Physician profile
Patrick C Cullinan
NPI 1043389653
$9,478.22
in general payments reported to CMS, 2019-2025
19 companies · $628 in 2025
The $628 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2021: $115 · 2022: $351 · 2023: $3,754 · 2024: $4,312 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $4,700 · Food and Beverage: $3,604 · Travel and Lodging: $315 · Education: $75.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $4,700.00 |
| Food and Beverage | $3,603.52 |
| Travel and Lodging | $315.00 |
| Education | $75.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fisher Scientific Company L.L.C. | $5,951.86 | 2023-2024 | Procalcitonin |
| Abbvie INC. | $814.43 | 2023-2025 | Avycaz, Teflaro, Dalvance |
| Astrazeneca Pharmaceuticals LP | $426.39 | 2022-2023 | Andexxa, Lokelma |
| Kerecis Limited | $299.91 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Actelion Pharmaceuticals US, INC. | $248.03 | 2024-2025 | Uptravi, Opsumit |
| Sobi, INC | $200.74 | 2024 | |
| Stryker Corporation | $152.54 | 2023 | Physio - Lucas |
| Medtronic, INC. | $133.24 | 2023 | Linq II |
| Neurocrine Biosciences, INC. | $128.34 | 2023 | Ongentys |
| Abbott Laboratories | $125.12 | 2023 | Amplatzer Amulet |
| Piramal Critical Care | $124.98 | 2022 | |
| Alexion Pharmaceuticals, INC. | $122.07 | 2019 | |
| Alcresta Therapeutics, INC. | $121.83 | 2024 | Relizorb |
| Bayer Healthcare Pharmaceuticals INC. | $121.36 | 2025 | |
| Mylan Specialty L.P. | $119.78 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $114.99 | 2021 | |
| Paratek Pharmaceuticals, INC. | $109.01 | 2025 | Nuzyra |
| Chiesi USA, INC. | $87.64 | 2024 | Cleviprex |
| Btg International INC. | $75.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Cullinan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.